Telix Pharmaceuticals (ASX:TLX) - CEO, Christian Behrenbruch
CEO, Christian Behrenbruch
Source: Telix Pharmaceuticals
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • Telix Pharmaceuticals (TLX) sees its review period for its prostate cancer imaging product extended by three months by the FDA
  • The extension was a result of the company’s Pre-Authorisation Inspection taking place after its initial late-cycle review meeting, which raised manufacturing-related observations
  • The US Food and Drug Administration (FDA) set a revised target date of 23 December 2021 for Illuccix, which will allow the FDA to review and consider further manufacturing-related information submitted by the company
  • Telix Pharmaceuticals is down 6.32 per cent, trading at $6.37 at 11:46 am AEST

Telix Pharmaceuticals (TLX) has seen its review period for its prostate cancer imaging product extended by three months by the FDA.

The US Food and Drug Administration (FDA) has set a revised target date of 23 December 2021 for Illuccix, Telix’s new drug application. This will allow the FDA to review and consider further manufacturing-related information submitted by the company, and is considered a standard review extension period.  

Telix sat down to a late-cycle review meeting with the FDA in June, during which time the authority indicated there were no substantivate manufacturing or clinical review issues with Telix’s product.

However the date of the company’s Pre-Authorisation Inspection (PAI) was after the meeting and it raised a set of manufacturing-related observations. Telix has since responded to those observations which the FDA is reviewing.

Telix CEO Christian Behrenbruch explained: “The timing of our PAI relative to the late-cycle review meeting meant that additional review time was needed to address manufacturing-related observations”.

“We look forward to being in a position to bring to patients in the US access to this flexible, highly specific and sensitive imaging tool for the detection of prostate cancer,” Dr Behrenbruch said.

Telix Pharmaceuticals was down 6.32 per cent, trading at $6.37 at 11:46 am AEST.

TLX by the numbers
More From The Market Herald

" Resonance Health (ASX:RHT) contracted for third party liver disease study

Resonance Health (ASX:RHT) has been contracted to provide liver-fat quantification services for a clinical study to…

" Cann Group (ASX:CAN) granted GMP licence by TGA

Cann Group (ASX:CAN) receives a GMP licence from the Therapeutic Goods Administration (TGA) to manufacture therapeutic…
1st Group (ASX:1ST) - Managing Director, Klaus Bartosch

" 1st Group (ASX:1ST) shares rise on Visionflex acquisition

Digital health company 1st Group (ASX:1ST) was up as much as 25 per cent on the…
Atomo Diagnostics (ASX:AT1) - Managing Director, John Kelly

" Atomo Diagnostics (ASX:AT1) sees growth in cash receipts as demand for rapid antigen tests soars

Atomo Diagnostics (ASX:AT1) sees growth in cash receipts as demand for rapid antigen tests soars